Bosch Healthcare Solutions GmbH
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
mehr
Storys zum Thema Impfung
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
mehrBioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare
Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that as part of BioVaxys' efforts to refocus on immunotherapeutics, Biovaxys and Procare Health ("Procare") have jointly and amicably agreed to terminate the US Distribution Agreement for Papilocare and Immunocaps. The partnership ...
mehrLTS Lohmann Therapie-Systeme AG
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
mehrTechnische Universität München
Vaccination campaign messages often prove ineffective
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de NEWS RELEASE Vaccination campaign messages often prove ineffective Study in eight countries demonstrates barriers for communications on Covid-19 Conventional vaccination campaign messages often miss their targets. A study in eight European countries shows that information on the benefits of ...
mehrQ-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
BOSTON, MA (ots) - --News Direct-- Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose ...
mehrALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS
mehrTechnische Universität München
A medication against SARS-CoV-2 – new strategy also promises protection against future SARS-CoV-2 variants
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37076 High resolution images: https://mediatum.ub.tum.de/1637268 NEWS RELEASE A medication against ...
mehr- 2
R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
mehr - 2
German MECOTEC Group delivers 8 containers for deep-freeze storage of Covid-Vaccines
mehr Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...
mehr- 6
Press Release MAHLE Covid-19 worldwide vaccination initiatives
mehr Technische Universität München
New approach identifies T cells in Covid-19 patients
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36882/ NEWS RELEASE New approach identifies T cells in Covid-19 patients Immune cell profile reveals appearance, number and activity level against SARS-CoV-2 T cells play a decisive role in fighting the ...
mehrTechnische Universität München
The virus trap: hollow nano-objects made of DNA could trap viruses and render them harmless
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36810/ High resolution images: https://mediatum.ub.tum.de/1616943 NEWS RELEASE The virus trap Hollow ...
mehrTechnische Universität München
Versatile, fast and reliable: new automated microarray rapid test detects SARS-CoV-2 antibodies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36762/ High resolution images: https://mediatum.ub.tum.de/1615381 NEWS RELEASE Versatile, fast and reliable SARS-CoV-2 antibody assay Automated microarray ...
mehrDid my vaccine work? New rapid test for the determination of vaccination success
mehrFirst pocket inhaler for Covid-19 and other viral mutations
Buochs (ots) - DG-Nika AG – a new approach to therapy & proactive protection from the pandemic The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-Nika AG research team has developed a solution for a new approach to protecting the ...
mehrHellmann provides Germany-wide distribution of COVID-19 vaccines for the government
mehrnal von minden plans to produce 80 million rapid corona tests per month
mehr- 2
German MECOTEC Group launches one-stop-solution for deep-freeze, transport, storage and distribution for COVID-19-Vaccines with its first Mobile Hybrid Container
mehr Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
mehrTechnische Universität München
Immune response: memory T cells are formed earlier than previously thought
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36297/ NEWS RELEASE How the immune system remembers viruses Immune response: memory T cells are formed earlier than previously thought For a person to ...
mehrNew: Combined rapid test for Covid-19 and influenza
mehrIgNova files patent application on antibody against COVID-19
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...
mehrNew in-vivo study confirms that ciliate vaccine protects against flu
mehr
1